Divestiture

The specialty minerals giant reports solid Q4 earnings while announcing a major strategic shift away from industrial ventures to focus on high-growth areas.

Hecla Mining posts a record $1.4B year, slashes debt, and sells a major gold mine to double down on its strategy to dominate the North American silver market.

RioCan posts strong 2025 results with near-full occupancy, but massive valuation losses and a development strategy shift reveal a complex picture.

Global X has terminated three ETFs, a strategic move that highlights key shifts in the booming Canadian ETF landscape. Here's what it means for investors.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

After a landmark bankruptcy, the medical giant is shoring up its finances. But can it overcome staffing shortages and shifting industry pressures?

An upcoming DC workshop highlights how public-private partnerships are modernizing federal facilities, saving energy, and bolstering national security.

Don Allan Jr. takes the helm at Els for Autism, a move poised to accelerate the foundation's mission with major corporate backing and strategic leadership.

50 years after a historic win put Napa on the map, Stag's Leap Wine Cellars celebrates with rare wines, luxury events, and a sustainable future.

Accord Healthcare's launch of generic lenalidomide signals a new era of affordability for a key cancer drug, intensifying competition and lowering costs.

NexLiving sells a Quebec property at a premium and declares a dividend, showcasing a dual strategy of aggressive growth and steady shareholder returns.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

New Commerce Dept. duties on Chinese graphite aim to reshape the U.S. battery industry, but will it secure the supply chain or just raise EV costs?

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

After a year of major acquisitions and divestitures, the packaging giant posts surging profits and outlines a simplified, focused strategy for 2026.

Armada Hoffler rebrands as AH Realty Trust, divesting multifamily and construction assets to slash debt and double down on the retail and office sectors.

Safe Bulkers sells a 14-year-old ship for $35.2M, capitalizing on a strong market to fund a new generation of eco-friendly vessels.

As state and federal cuts threaten vital services, Bloomington Health Foundation offers critical bridge funding to stabilize local nonprofits on the brink.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.